Asthma treatment

http://www.healasthma.com past six monthsthe past twelve months Search Hint Use the source navigation bar below to quickly narrow or broaden your search by geographic area. – . wire (USA) – Wal-Mart Brings Generics Program to Massachusetts, Customer demand leads to prescription program launching in more states today; new prescriptions added to the program PRNewswire-FirstCall — Wal-Mart Stores, Inc., (NYSE WMT) announced that its pharmacies in Massachusetts will begin participating in Wal-Mart’s generic prescription program starting today. In addition, the company announced that it is adding more prescriptions to the program. “We’ve received an amazing amount of positive feedback from the millions of seniors, working families and uninsured who are already taking advantage of this… Wal-Mart will slash prices on its drugs Wal-Mart will slash prices on its drugs Some of the generic prescription medicines will be sold for as little as for a month’s supply By ANNE D’INNOCENZIO AP Business Writer NEW YORK – Wal-Mart, the world’s largest retailer, plans to slash the prices of almost generic prescription drugs, offering a big lure for bargain-seeking customers and presenting a challenge to competing pharmacy chains and makers of generic drugs.The drugs will be sold… . FD (FAIR DISCLOSURE) WIRE – Event Brief of Q Apria Healthcare Group Earnings Conference Call – Final PARTICIPANTS . Larry Higby, Apria Healthcare Group, CEO . Amin Khalifa, Apria Healthcare Group, CFO . Arthur Henderson, Jefferies & Company, Analyst . David MacDonald, SunTrust, Analyst . Kevin Fischbeck, Lehman Brothers, Analyst . Eric Gommel, Stifel Nicolaus, Analyst . Chad Poujare, Wachovia Securities, Analyst . Balaji Gandhi, Oppenheimer, Analyst . Gary Taylor, Banc of America, Analyst . Alicia Price, Apria Healthcare Group, VP,… . FD (FAIR DISCLOSURE) WIRE – Adams Respiratory Therapeutics at Morgan Stanley Global Healthcare Unplugged Conference – Final UNIDENTIFIED CORPORATE REPRESENTATIVE [begins in progress]. Before I begin I have to read a disclosure. Please see important disclosures including Morgan Stanley analysts’ personal [inaudible], disclosures of Morgan Stanley disclosures available as a handout both in the foyer area and at the Morgan Stanley corporate website. I think Mike wanted to open with some remarks before we get into a Q&A, so — MIKE VALENTINO, CEO, ADAMS RESPIRATORY THERAPEUTICS Thanks… . FD (FAIR DISCLOSURE) WIRE – Adams Respiratory Therapeutics at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference – Final OPERATOR Good morning and welcome to the Adams Day. Leading specialty pharmaceutical company focusing on the OTC and prescription, respiratory therapeutics market. Kicking off the presentation for the company this morning is Janet Barth, Adams’ VP of Investor Relations. JANET BARTH, EXECUTIVE DIRECTOR, INVESTOR AND PUBLIC RELATIONS, ADAMS RESPIRATORY THERAPEUTICS Thank you Elliot and good morning everyone. Today I’m joined by Mike Valentino our President and… . FD (FAIR DISCLOSURE) WIRE – Adams Respiratory Therapeutics at Deutsche Bank Securities Small Cap Growth Conference – Final UNIDENTIFIED COMPANY REPRESENTATIVE Our next company to present this morning is Adams Respiratory. They’re a new story, given that the company’s IPO was actually one of the best IPOs of last year. Stock was up in access of %. The company is somewhat unique in specialty pharma as it’s flagship product, Mucinex, is primarily promoted directly through consumer advertising rather than through specialty physicians. So anyway, here to tell us more about the… . Los Angeles Times Drug Costs Are Target of Long Beach Hospital Pharmacist Melinda Klein scours studies and patrols the halls in an effort to ensure smart spending. When Sepracor Inc. wanted Long Beach Memorial Medical Center to use more of its asthma medicine, the company went to see Melinda Klein.Three published studies touted the benefits of Xopenex for asthma patients requiring emergency care. But Klein, a Memorial pharmacist, thought the medicine looked no better than an inexpensive generic drug.Klein recommended keeping Xopenex off the hospital’s list of preferred medicines, or formulary. A hospital committee of doctors, nurses… . FD (FAIR DISCLOSURE) WIRE – Q Ivax Earnings Conference Call – Final OPERATOR Ladies and gentlemen, thank you for standing by. Welcome to the IVAX Corporation third quarter earnings call. [OPERATOR INSTRUCTIONS]. I would like to now turn the conference over to our host, Mr. Neil Flanzraich, vice chair and president. Sir, you begin. NEIL FLANZRAICH, VICE CHAIRMAN AND PRESIDENT, IVAX CORPORATION Thank you. Good morning, everyone. I’m Neil Flanzraich, Vice Chairman and President of IVAX corporation. Phillip Frost, Chairman and CEO of IVAX… . FD (FAIR DISCLOSURE) WIRE – Event Brief of Q Ivax Earnings Conference Call – Final PARTICIPANTS . Neil Flanzraich, IVAX Corporation, Vice Chairman and President . David Malina, IVAX Corporation, VP IR . Tom Beier, IVAX Corporation, CFO OVERVIEW IVX reported Q net income of . m or . per share. YTD income was . m or . per share. No specific earnings guidance was given in view of IVX’s merger with Teva. FINANCIAL DATA A. Key Data From Call . Q revenues = . m. . YTD revenues = . b. . Q net… . FD (FAIR DISCLOSURE) WIRE – Event Brief of Q Ivax Earnings Conference Call – Final PARTICIPANTS . Neil Flanzraich, IVAX Corporation, Vice Chairman and President . David Malina, IVAX Corporation, VP IR . Tom Beier, IVAX Corporation, CFO OVERVIEW IVX reported Q net income of . m or . per share. YTD income was . m or . per share. No specific earnings guidance was given in view of IVX’s merger with Teva. FINANCIAL DATA A. Key Data From Call . Q revenues = . m. . YTD revenues = . b. . Q net… –